News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diosynth Biotechnology (Research Triangle Park) Announces Agreement With ImmunoGen, Inc. (IMGN)



10/19/2005 5:13:18 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 6, 2005--Diosynth Biotechnology, Inc. is pleased to announce the execution of an agreement with ImmunoGen, Inc. (Cambridge, MA) for the production of antibody to be used in the manufacture of ImmunoGen's huN901-DM1 anticancer compound.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES